Evolent Health, Inc. Stock

Equities

EVH

US30050B1017

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:02 2024-05-10 pm EDT 5-day change 1st Jan Change
24.46 USD -9.27% Intraday chart for Evolent Health, Inc. -9.74% -25.95%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.56B Sales 2025 * 2.93B Capitalization 2.8B
Net income 2024 * -5M Net income 2025 * 92M EV / Sales 2024 * 1.2 x
Net Debt 2024 * 273M Net Debt 2025 * 242M EV / Sales 2025 * 1.04 x
P/E ratio 2024 *
107 x
P/E ratio 2025 *
25 x
Employees 4,700
Yield 2024 *
1.11%
Yield 2025 *
1.04%
Free-Float 94.78%
More Fundamentals * Assessed data
Dynamic Chart
UBS Trims Price Target on Evolent Health to $44 From $46, Keeps Buy Rating MT
Evolent Health Q1 Adjusted Earnings, Revenue Rise; Q2 Revenue Guidance Set, 2024 Revenue Outlook Increased MT
Transcript : Evolent Health, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (EVH) EVOLENT HEALTH Posts Q1 EPS $0.34, vs. Street Est of $0.30 MT
Earnings Flash (EVH) EVOLENT HEALTH Posts Q1 Revenue $639.7M, vs. Street Est of $598.9M MT
Evolent Health, Inc. and Careology Form Strategic Care Navigation Partnership to Enhance Cancer Care in the U.S CI
Evolent Health, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Raises Earnings Guidance for the Full Year Full Year Ending December 31, 2024 CI
Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target MT
Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating MT
JPMorgan Trims Price Target on Evolent Health to $52 From $53, Maintains Overweight Rating MT
Transcript : Evolent Health, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Canaccord Genuity Cuts Price Target on Evolent Health to $45 From $47, Maintains Buy Rating MT
Evolent Health Q4 Adjusted Income, Revenue Rise; Q1, 2024 Revenue Guidance Set; Shares Jump After Hours MT
Transcript : Evolent Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (EVH) EVOLENT HEALTH Reports Q4 EPS $0.23, vs. Street Est of $0.15 MT
More news
1 day-9.27%
1 week-9.74%
Current month-11.82%
1 month-19.88%
3 months-20.33%
6 months-12.64%
Current year-25.95%
More quotes
1 week
23.87
Extreme 23.87
27.72
1 month
23.87
Extreme 23.87
30.66
Current year
23.87
Extreme 23.87
35.00
1 year
23.33
Extreme 23.33
35.52
3 years
18.30
Extreme 18.3
39.78
5 years
3.50
Extreme 3.5
39.78
10 years
3.50
Extreme 3.5
39.78
More quotes
Managers TitleAgeSince
Founder 45 11-07-31
President - 22-09-14
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member 70 20-01-31
Director/Board Member 59 23-06-07
Chairman 74 15-10-31
More insiders
Date Price Change Volume
24-05-10 24.46 -9.27% 5,291,035
24-05-09 26.96 -1.14% 1,637,292
24-05-08 27.27 -1.23% 935,647
24-05-07 27.61 +1.36% 1,398,885
24-05-06 27.24 +0.52% 1,120,539

Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT

More quotes
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
24.46 USD
Average target price
43.29 USD
Spread / Average Target
+76.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW